secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001493152-26-005555
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENvue Medical amends CEO equity plan, appoints David Johnson as Chairman with 3.5% RSU grant
--------------------------------------------------------------------------------

- Amendment changes CEO Doron Besser's equity grants from annual to quarterly, with prorated gross-up on termination without cause.
- David Johnson appointed Chairman; receives $10k/month and RSUs representing 3.5% of fully diluted common stock.
- Chairman's RSUs vest over 2 years with anti-dilution protection; agreement auto-renews annually unless terminated.
- Besser's initial RSU grant remains 9% of fully diluted shares, subject to Israeli Tax Authority approval.
- Both agreements effective February 2, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315226005555/0001493152-26-005555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315226005555/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer